Background It has been suggested that high cholesterol represents a risk factor for Graves' orbitopathy (GO). In a recent cross-sectional study, a correlation between cholesterol and the presence of GO was found in patients with a Graves' disease (GD) of recent onset. To confirm this observation, we conducted a retrospective investigation in consecutive patients with GD. The primary outcome was the relationship between the presence of GO and low-density lipoprotein (LDL)-cholesterol. Methods The design entailed the inclusion of consecutive patients with a GD of recent onset, with or without GO, who came to our observation to receive radioiodine over a period of 6 months, and a stratification aimed at having two homogeneous group of patients in terms of thyroid function. A total of 86 patients fulfilled the inclusion and evaded the exclusion criteria. All patients underwent an ophthalmological assessment and serum lipids were measured. Results Serum levels of LDL-cholesterol were significantly higher in patients with GO (135.3 ± 41.3 mg/dL) compared with those without GO (106.6 ± 23.9 mg/dL, P = 0.0007). In a similar manner, serum levels of total cholesterol were higher in patients with GO (211.6 ± 44.0 mg/dL) than in those without GO (176.0 ± 27.2 mg/dL, P = 0.0001). There was no relationship between GO severity and activity and cholesterol. There was no relationship between GO and high-density lipoproteincholesterol or triglycerides. Conclusions Our study confirms a relationship between the presence of GO and cholesterol in patients with GD of recent onset. Whether lowering of cholesterol ameliorates, GO remains to be established.
Introduction
Recent studies have suggested that high cholesterol levels represent a risk factor for Graves' orbitopathy (GO) [1, 2] , the most common extrathyroidal manifestation of Graves' disease (GD) [3, 4] . In addition to genetic and demographical variables [4] , established GO risk factors in GD are sex, age, insufficient control of hyperthyroidism, treatment with radioiodine, uncontrolled hypothyroidism, and smoking [5] [6] [7] [8] [9] [10] [11] [12] [13] . Stein et al. reported that treatment with 3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors, commonly known as statins, is associated with a reduced risk of developing GO in patients with GD [1] . The study was conducted in more than 8000 subjects with a GD of recent onset, having data been collected from a managed-care network database (Clinformatics database). The authors observed a 40% reduced risk of GO in patients on statins and, together with other authors, interpreted the findings as the consequence of the anti-inflammatory action of statins [1, 14] . The latter interpretation was based on the fact that GO is generally identified as an inflammatory condition [15] , reflecting an autoimmune aggression against autoantigens expressed both by the thyroid and orbital fibroblasts, and ultimately leading to the activation of secondary mechanisms that involve mediators of inflammation and oxidative stress [15, 16] , all features that could be counteracted by the anti-inflammatory action of statins.
The use of statins for hypercholesterolemia is established since a relatively long time [17] . As many other medications, statins may have adverse reactions. In patients with GO, they have been postulated to increase the risk of glucocorticoidinduced hepatitis [18] , although a population study on the subject was overall reassuring [19] . We considered the possibility that the protective effect of statins on GO may reflect not only the anti-inflammatory action of these medications, but also, or rather, their hypolipemic effect. In this regard, we recently performed a cross-sectional study in which we observed a positive correlation between cholesterol and the presence of GO in patients with a GD of recent onset, suggesting that high serum cholesterol is a GO risk factor [2] . In addition, we found a correlation between cholesterol and the activity of GO in untreated patients, suggesting that the lipid status may affect the clinical expression of GO [2] . To confirm these observations, here, we conducted a retrospective study in consecutive patients with GD. The primary outcome was the relationship between the presence of GO and lowdensity lipoprotein (LDL)-cholesterol. The secondary outcomes were the relationship between GO clinical expression (severity and activity) and LDL-cholesterol, the relationship between GO and total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides, and the association between GO and high LDL-cholesterol, high total cholesterol, low HDL-cholesterol, and high triglycerides.
Methods

Study design
The aim of the study was the relationship between GO and serum LDL-cholesterol in GD patients in a retrospective investigation. The design entailed the inclusion of all consecutive GD patients, with or without GO, who came to our observation to receive radioiodine treatment over a period of 6 consecutive months.
Setting
The study was carried out in the GO Clinic of the Endocrinology Units I and II and of the Ophthalmopathy Unit I of the University Hospital of Pisa, a tertiary referral center. Data were collected by means of consecutive sampling from the clinical files of patients who came to our observation from July 1st until December 31th 2014. Data were collected by GL, MAP, BM, AS, RR ML, and FM and were recorded in a computer-assisted database. The study was not blinded. The following validation procedures were employed for database data collection: allowed character checks, batch totals, missing records check, cardinality check, digits check, consistency check, control totals, cross-system consistency check, data type check, hash totals, limit check, logic check, presence check, range check, spelling and grammar check, and uniqueness check.
Participants
Inclusion criteria: (1) a diagnosis of GD in patients who were scheduled to undergo radioiodine treatment, and consequently, who had discontinued anti-thyroid medications since 1-3 days; (2) a history of hyperthyroidism lasting no more than 44 months, based on previous evidence that GO is associated with high cholesterol levels in patients with a relatively short duration of hyperthyroidism [2] ; in this regard, in our previous study, a 44 month cut-off was shown to separate significantly GD patients in those in whom there was an association between GO and cholesterol and those without a similar association [2] ; (3) no previous treatments for GO, when present; and (4) informed consent to data use.
Exclusion criteria: (1) earlier treatment of hyperthyroidism by methods other than anti-thyroid medications, namely, thyroidectomy or radioiodine; (2) a duration of hyperthyroidism > 44 months; (3) previous treatments for GO other than eye lubricants; and (4) lack of informed consent to data use. Data were collected from a total of 86 consecutive patients seen in the period reported above, in whom inclusion criteria were satisfied and exclusion criteria evaded.
Outcomes
The primary outcome of the study was the relationship between the presence of GO and serum LDL-cholesterol.
The secondary outcomes were:
(1) the relationship between GO severity, assessed by means of the NOSPECS score [20, 21] and LDL-cholesterol. NOSPECS stands for no GO signs (N), only eyelid signs (O), soft-tissue involvement (S), proptosis (P), extra-ocular motility restriction (E), corneal involvement (C), and sight loss (S), resulting in a numerical value, wherein each progressive class corresponds to a number from 1 to 6 [21] ; (2) the relationship between GO activity, assessed by means of the Clinical Activity Score (CAS) [20] , and LDL-cholesterol; (3) the relationship between the presence of GO and total cholesterol, HDL-cholesterol, and triglycerides; (4) the association between the presence of GO and high LDL-cholesterol, high total cholesterol, low HDL-cholesterol, and high triglycerides, all defined based on the recommendations of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [22] , namely: serum LDL-cholesterol was considered high when ≥ 115 mg/dL; total cholesterol was considered high when ≥ 190 mg/dL; HDL-cholesterol was considered low when ≤ 46 mg/dL in women and ≤ 40 mg/dL in men; and triglycerides were considered high when ≥ 150 mg/dL.
The presence of GO was defined by a NOSPECS Class ≥ 2, namely, in patients who had at least one of the following eye features: exophthalmometry ≥ 17 mm in women and ≥ 19 mm in men, based on measurements conducted for the normal population [23, 24] ; eyelid aperture ≥ 9 mm [25] ; (iii) CAS ≥ 1/7; (iv) presence of diplopia; (v) presence of corneal alterations; vi) presence of GO-related alterations of the fundi; and (vii) reduction in visual acuity that could be attributed to GO.
Sources of data and measurements
The following ophthalmological assessments were performed in all patients: (1) exophthalmometry, using an Hertel exophthalmometer; (2) eyelid aperture measurement; (3) CAS evaluation; (4) assessment of diplopia; (5) assessment of the corneal status; (6) examination of the fundi; and (7) visual acuity measurement.
In all patients, the following serum tests were performed: FT 4 and FT 3 (Vitros Immunodiagnostics, Raritan, NJ); TSH (Immulite 2000, Siemens Healthcare, Gwynedd, UK); anti-TSH receptor antibodies (TRAb, Brahms, Berlin, Germany); total cholesterol (Roche, Mannheim, Germany); LDL-cholesterol (Roche); HDL-cholesterol (Roche); and triglycerides (Roche).
We recorded smoking habits, physical activity (at least 30 min of exercise three times a week), and alcohol consumption (at least 50 g of ethanol/week) in all patients.
Finally, conditions or treatments that can potentially affect cholesterol levels were recorded, including diabetes, chronic renal failure, therapy with statins, or estroprogestins.
Potential bias
As in our previous study [2] , and as mentioned above, the study design entailed the inclusion of GD patients who came for our observation to undergo treatment with radioiodine. This stratification was aimed at having two distinct groups of patients under the same conditions, namely, 2-3 days after the discontinuation of anti-thyroid medications, which should have minimized the impact of thyroid function on cholesterol levels, considering that both hyper-and hypothyroidism can affect cholesterol.
Sample size
We estimated that a total of 166 GD patients would have been needed to observe a difference in serum LDL-cholesterol levels (the primary outcome) between patients with GO and patients without GO similar to that reported in our previous study [2] , with a statistical power of 0.8 and a P value ≤ 0.05. At the end of the recruitment period, the number of patients recruited, namely, 86, did not reach the calculated sample size. However, because the findings were significantly different between patients with or without GO for the primary outcome measure, we considered this number of patients sufficient.
Informed consent
Signed informed consent was obtained from all patients.
Quantitative variables
Numerical data with a normal distribution, which was assessed using the Shapiro-Wilks test, are presented as mean ± SD. The remaining numerical data are presented as median and IQR.
Statistical analyses
When appropriate, the following tests were performed: (i) t test; (ii) Mann-Whitney; (iii) Chi square; and (iv) linear regression.
Results
Participants
Of the 86 patients studied, 55 had a clinically relevant GO ( Table 1) . As in our previous study [2] , the proportion of patients with GO was higher than that reported previously [3] , reflecting the fact that, compared to primary care or secondary referral centers, in our tertiary referral center for GO, a greater proportion of GD patients also suffers from GO [3] . There were no differences between patients with or without GO concerning age, sex, familial history of hypercholesterolemia, smoking habits, extent of physical activity, alcohol consumption, body mass index (BMI), proportion of patients with conditions that could affect cholesterol levels (diabetes and chronic liver failure), and proportion of patients taking medications that could affect cholesterol levels, namely, statins and estroprogestins, time since the diagnosis of hyperthyroidism, serum FT 4 , FT 3 , TSH, thyroid status, and TRAb.
Primary outcome data: relationship between the presence of GO and serum LDL-cholesterol
As shown in Fig. 1a and in confirmation of our previous study [2] , serum levels of LDL-cholesterol were significantly higher in patients with GO compared with patients without GO (P = 0.0007 by t test). Interestingly, mean levels of LDLcholesterol in patients without GO (106.6 ± 23.9 mg/dL, range 51-162) were below 115 mg/dL, namely, the cut-off value established by ESH and ESC to define a subject hypercolesterolemic [22] . In contrast, mean LDL-cholesterol levels in patients with GO (135.3 ± 41.3 mg/dL, range 70-266) were well above the cut-off value.
Secondary outcome data
(1) Relationship between GO severity and LDL-cholesterol.
GO severity, assessed using the NOSPECS score [21] , did not correlate with LDL-cholesterol levels (not shown). In line with this observation, the NOSPECS score did not differ between GO patients with high LDL-cholesterol (≥ 115 mg/ dL) and those with normal LDL-cholesterol (not shown).
(2) Relationship between GO activity and LDL-cholesterol.
There was no relationship between GO activity, namely, the CAS, and serum LDL-cholesterol (not shown). In agreement with these findings, the CAS did not differ between GO patients with or without high serum LDL-cholesterol (not shown).
(3) Relationship between the presence of GO and serum total cholesterol, HDL-cholesterol, and triglycerides.
As shown in Fig. 1b , serum levels of total cholesterol were higher (P = 0.0001 by t test) in patients with GO (211.6 ± 44.0 mg/dL, range 130-349) compared with those without GO (176.0 ± 27.2 mg/dL, range 101-239). As for LDL-cholesterol, mean levels of total cholesterol in patients without GO were normal, namely, below 190 mg/ml, the cut-off level established by ESH and ESC [21] , whereas mean levels of total cholesterol in patients (4) Association between the presence of GO and high LDL-cholesterol, high total cholesterol, low HDLcholesterol, and high triglycerides.
As shown in Fig. 2a , the proportion of patients with high LDL-cholesterol (≥ 115 mg/dL) was greater in patients with GO compared with those without GO (P < 0.0001 by Chi square). Similarly, the proportion of patients with high total LDL-cholesterol (≥ 190 mg/ dL) was greater in patients with GO (P < 0.0001 by Chi square). In contrast, the prevalence of patients with low HDL-cholesterol (≤ 46 mg/dL in women and ≤ 40 mg/dL in men) or with high triglycerides (≥ 150 mg/dL) did not differ between patients with or without GO (not shown).
Discussion
Recent investigations have suggested that cholesterol may represent a risk factor for GO. Stein et al. showed a protective effect of statins in terms of GO development in patients with a GD of recent onset [1] . In a cross-sectional study, we observed a correlation between the presence of GO and high cholesterol (both total and LDL-bound), as well as a correlation between cholesterol and GO activity in untreated patients [2] . In the present, retrospective study, we confirmed the association between the presence of GO and high cholesterol levels in GD patients, whereas we failed in demonstrating a correlation between GO severity or activity and cholesterol. Results in support of our conclusions are summarized and discussed in the following sections.
We studied 86 eligible consecutive patients with GD, with or without GO, who came to our observation to undergo radioiodine treatment, a stratification aimed at having two groups of patients under the same conditions and at minimizing the effects of thyroid function on cholesterol, as we did in our previous study [2] . The aim of the stratification was fulfilled, as thyroid function was similar in patients with GO compared with those without GO. All of the other variables that could affect cholesterol levels, namely, age, sex, familial history of hypercholesterolemia (which does not imply familial hypercholesterolemia), physical activity, alcohol consumption, BMI, diabetes, chronic liver failure, and cholesterol-lowering medications did not differ between the two study groups. In this regard, it is quite relevant to underscore that only a minority of patients were on statin treatment and that, therefore, the effect of this variable on the results was negligible. The time since the diagnosis of hyperthyroidism was similar in the two groups, reflecting the inclusion of patients with a history of hyperthyroidism lasting no longer than 44 months, which was derived from our previous study in which we observed a correlation between cholesterol levels and GO exclusively in patients with a hyperthyroidism of recent onset, namely, ≤ 44 months [2] . Having established that the two groups (GO vs no GO) were fairly comparable, we found significantly higher LDLcholesterol (the primary outcome) and total cholesterol in patients with GO, compared with those without GO, in confirmation of which, the proportion of patients with LDLcholesterol and total cholesterol levels above the upper limit of the normal range was significantly and remarkably greater in patients with GO. The latter observations clearly confirm that cholesterol is a risk factor for GO development in GD patients. In confirmation of our previous study [2] , we did not find any relationship between the presence of GO, HDLcholesterol, and triglycerides. We did not observe a correlation between the features of GO, namely, severity and activity, and cholesterol. In our previous study [2] , GO severity and activity were minimally affected by serum lipids, although CAS values were higher in GO patients with high total cholesterol. However, when the analysis was restricted to untreated patients, we found a significant correlation between CAS and both total and LDL-cholesterol [2] . The reasons for the discrepancy between our previous and present study are unknown. They may reflect the retrospective nature of the present study, with the possible, consequent limitations, the smaller sample size compared with our previous study [2] , or the inclusion only of patients with a short duration of hyperthyroidism. Clearly, further studies are needed to investigate whether the clinical expression of GO is affected by cholesterol.
Concerning the mechanisms responsible for the relation between GO and cholesterol, they may be related to the altered inflammatory state of hypercholesterolemia. In this regard, disorders of lipid metabolism are known to be associated with a state of mild-to-moderate, systemic, chronic inflammation [26, 27] . For example, in the liver, an increased load of free fatty acids causes dysfunction of the mitochondria and endoplasmic reticulum of hepatocytes, thereby leading to the release of reactive oxygen radical species [26] . In addition, free fatty acid can indirectly cause the release of pro-inflammatory cytokines, namely, interleukin-6 and tumor necrosis factor-α, both involved in the pathogenetic mechanisms of GO [15, 16] . Both in our previous and the present study, we did not observe an association between GO and triglycerides, which militates against the possibility that free fatty acids are involved in GO. In support of an altered inflammatory state in hypercholesterolemia as the cause of the link between GO and high cholesterol, Busnelli et al. observed a protective effect of statins in terms of systemic inflammation in swine [27] . Obviously, these explanations are speculative and further investigations are required.
In conclusion, our study confirms a relation between the presence of GO and cholesterol in patients with GD of relatively recent onset, with the due clinical implications, especially concerning the possibility that lowering of cholesterol levels may be associated with improved GO outcomes.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Ethical approval All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from the individual participant included in the study.
